Phio Pharmaceuticals
PHIO
16 hedge funds and large institutions have $991K invested in Phio Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 3 closing their positions.
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
7% more funds holding
Funds holding: 15 → 16 (+1)
0.01% more ownership
Funds ownership: 0.06% → 0.07% (+0.01%)
46% less capital invested
Capital invested by funds: $1.82M → $991K (-$832K)
61% less call options, than puts
Call options by funds: $13K | Put options by funds: $33K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$128K |
| 2 |
Two Sigma Advisers
New York
|
+$87.6K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$27.7K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$25.6K |
| 5 |
Renaissance Technologies
New York
|
+$15K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$114K |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$83K |
| 3 |
TCWM
Total Clarity Wealth Management
St. Charles,
Illinois
|
-$3K |
| 4 |
JP Morgan Chase
New York
|
-$636 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$159 |
PHIO Hedge Fund Activity: Q4 2021 in Review
16 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2021, worth a combined $991K — down 46% from $1.82M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PHIO positions and 3 closed out — a net gain of 1 holder — while 7 added to existing stakes and 2 trimmed.
The largest buyer was Two Sigma Investments, adding an estimated $128K. The largest seller was Millennium Management, cutting an estimated $114K.
- 16 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2021, up from 15 in Q3 2021.
- Funds reported $991K of Phio Pharmaceuticals stock for Q4 2021, down 46% quarter-over-quarter.
- 4 funds opened new Phio Pharmaceuticals positions in Q4 2021 and 3 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q4 2021 was Two Sigma Investments, an estimated $128K added.
- The largest Phio Pharmaceuticals seller in Q4 2021 was Millennium Management, an estimated $114K sold.
Based on aggregated 13F filings for Q4 2021.